Inactive Instrument

Grindeks AS Stock Nasdaq Riga

GRD1R

LV0000100659

Pharmaceuticals

End-of-day quote Nasdaq Riga Other stock markets
- ^LVL	-

24-04-03	Grindeks Opens New Subsidiaries Worldwide	CI
21-02-24	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Employees

Sector

Pharmaceuticals

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

24-04-03	Grindeks Opens New Subsidiaries Worldwide	CI
21-02-24	JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	CI
21-01-21	SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	CI
20-12-21	SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	CI
20-11-26	Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-27	Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-08-18	Akciju sabiedriba Grindeks Approves to Pay Dividend, Payable on September 17, 2020	CI
20-08-04	Akciju sabiedriba Grindeks Proposes to Pay Dividend, Payable on September 17, 2020 and November 17, 2020, Respectively	CI
20-03-05	Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	CI
20-02-28	As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-02-04	JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	CI
20-01-22	JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	CI
19-12-19	JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	CI

21-03-03	Grindeks : In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit	AQ
21-02-24	Grindeks : Andrejs Liberts appointed as the member of the board of JSC “Grindeks”	AQ
21-02-12	Grindeks : Delisting of AS „Grindeks” shares from the Baltic Main list	AQ
21-02-09	Grindeks : On exclusion of shares from the regulated market	AQ
21-01-26	Grindeks : Information about refusal to repurchase the final shares of JSC “Grindeks”	AQ

Manager	Title	Age	Since
Janis Romanovskis CEO	Chief Executive Officer	66	2010-04-21
Andrejs Liberts PRN	Corporate Officer/Principal	41	2021-02-23
Iveta Zomerfelde SAM	Sales & Marketing	-	2015-03-02

Director	Title	Age	Since
Kirovs Lipmans CHM	Chairman	85	2002-12-31
Anna Lipmane BRD	Director/Board Member	78	2007-12-31
Filips Lipmans BRD	Director/Board Member	48	2003-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.46%	+2.53%	+15.98%	+81.88%	48.52B
OTSUKA HOLDINGS CO., LTD.	-0.36%	-4.82%	+65.56%	+115.03%	35.68B
CIPLA LIMITED	-0.01%	-0.95%	-3.10%	+39.49%	12.09B
ZYDUS LIFESCIENCES LIMITED	+2.06%	+0.34%	+19.46%	+94.32%	11.77B
KRKA, D. D.	+1.13%	+0.38%	+32.83%	+126.50%	9.19B
ONO PHARMACEUTICAL CO., LTD.	-1.81%	-2.85%	+45.77%	-5.83%	7.06B
GEDEON RICHTER	-0.17%	-2.20%	+18.33%	+37.26%	7.01B
GLENMARK PHARMACEUTICALS LIMITED	-0.33%	+1.43%	+3.52%	+227.22%	6.77B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+6.39%	-0.15%	-14.91%	+20.63%	5.98B
Average	+0.82%	+0.42%	+20.38%	+81.83%	16.01B
Weighted average by Cap.	+0.46%	-0.27%	+27.72%	+88.21%

Grindeks AS Stock Nasdaq Riga

Stocks

GRD1R

LV0000100659

Pharmaceuticals

Latest news : Grindeks AS

Press Releases: Grindeks AS

Managers and Directors: Grindeks AS

Generic Pharmaceuticals

Company Profile